Analyst Profile

Followed by 480 followers
.
Keay Nakae

Keay Nakae

Chardan Capital
Wall Street Analyst
#3,083 out of 8,141 Wall Street Analysts
#7,051 out of 24,284 experts

Success Rate

37%
142 out of 381 transactions made a profit

Average Return

+1.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Keay Nakae's trades since 2012 and holding each position for 1 Year would result in 37.27% of your transactions generating a profit, with an average return of 1.8% per rating.

Stock Rating Distribution

478Ratings
85.98% Buy
12.34% Hold
1.67% Sell
Distribution of Keay Nakae's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
GermanyGermany Market
United KingdomUK Market

Best Rating

Stock:
Ocugen Inc
(OCGN)
Rating:Buy
Date:Nov 10, 2020 - Feb 09, 2021
Return:+800.00%
The most profitable rating made by Keay Nakae

Keay Nakae's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Vericel
May 16, 2012
Buy
Initiated
1Ratings
0%
-73.70%
SLTM
Solta Medical Inc
May 03, 2013
Buy
Assigned
1Ratings
100%
+63.10%
Theriva Biologics
Jun 25, 2013
Buy
Initiated
$2.30
(229.75% Upside)
1Ratings
100%
+0.50%
Biolase
Jul 03, 2013
Buy
Reiterated
$5.50
(441.87% Upside)
1Ratings
0%
-41.80%
Galectin Therapeutics
Oct 07, 2013
Buy
Initiated
$13.00
(907.75% Upside)
1Ratings
0%
-60.80%
Gadsden Properties
May 15, 2014
Hold
Downgraded
$18.00
(1636263.64% Upside)
3Ratings
50%
+0.25%
Plus Therapeutics
Aug 06, 2014
Hold
Downgraded
$4.00
(826.14% Upside)
1Ratings
0.00%
~RPRX
Repros
Aug 29, 2014
Buy
Reiterated
5Ratings
20%
-26.92%
Aldeyra Therapeutics
Dec 03, 2014
Buy
Initiated
$16.00
(193.04% Upside)
1Ratings
0%
-4.60%
NSPH
Nanosphere
Sep 08, 2015
Buy
Initiated
1Ratings
0%
-41.10%
List of latest recommendations made by Keay Nakae. Click to expand and see Keay Nakae's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >